Can a cancer drug protect new kidneys from scarring?
NCT ID NCT06751602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding belumosudil (Rezurock) to standard care can prevent scarring in new kidney transplants. About 40 adults receiving their first or second kidney will be randomly assigned to get the drug or a placebo for a year. The study tracks serious side effects and checks kidney tissue for scarring at 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Belumosudil (also known as Rezurock)
What this could lead to
If it works, this could point toward a way to prevent kidney scarring and extend transplant life without increasing rejection risk.
What could go wrong
This is a small, early-phase trial (40 people) testing a drug already approved for another condition. It may not show benefit, and side effects could occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Research Institute
Houston, Texas, 77030, United States